000			01686cam a2200289 a 4500
999			_c7404 _d7404
001			000024341
003			YEEZEN
005			20230210124652.0
008			080403s2008 mau r 001 0 eng d
020			_a9780123694485
020			_a0123694485
040			_aNHRI _c0
042			_anbic
060		4	_aQV269 _bN397
100	1		_aNeidle, Stephen.
245	1	0	_aCancer drug design and discovery _cStephen Neidle.
260			_aBoston _bAcademic Press _c2008.
300			_axv, 473 p., [27] p. of plates _bill. (some col.) _c27 cm.
504			_aIncludes bibliographical references and index.
505	0		_aPt. I Basic Principles.
505	0		_aPt. II Methodology.
505	0		_aPt. III Drugs in the Clinic.
505	0		_aPt. IV New Agents.
505	0		_aPt. V The Reality of Cancer Drugs in the Clinic.
520	3		_aThe ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours.
520	3		_aUnique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options.
650		0	_aAntineoplastic agents _xDevelopment.
650		0	_aAntineoplastic agents _xDesign.
942			_2NLM _cENGLIT